Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Capmatinib Hydrochloride Patent Expiration

Capmatinib Hydrochloride is Used for treating patients with metastatic non-small cell lung cancer with a mesenchymal-epithelial transition exon 14 skipping mutation. It was first introduced by Novartis Pharmaceutical Corp in its drug Tabrecta on May 6, 2020.


Capmatinib Hydrochloride Patents

Given below is the list of patents protecting Capmatinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tabrecta US10596178 Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide Jul 22, 2035 Novartis Pharm
Tabrecta US7767675 Imidazotriazines and imidazopyrimidines as kinase inhibitors Nov 19, 2027 Novartis Pharm
Tabrecta US8420645 Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same Jun 05, 2031 Novartis Pharm
Tabrecta US8461330 Imidazotriazines and imidazopyrimidines as kinase inhibitors Nov 19, 2027 Novartis Pharm
Tabrecta US8901123 Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same May 20, 2029 Novartis Pharm


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Capmatinib Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Capmatinib Hydrochloride.

Event Date Patent/Publication
Patent litigations
Notice of Final Determination -Election Required 18 Apr, 2024 US7767675
Notice of Final Determination -Election Required 18 Apr, 2024 US8420645
Resp. to req. for info. sent under 37 CFR 1.750 08 Dec, 2023 US7767675
Resp. to req. for info. sent under 37 CFR 1.750 08 Dec, 2023 US8420645
Email Notification 20 Nov, 2023 US8461330
Change in Power of Attorney (May Include Associate POA) 20 Nov, 2023 US8901123
Change in Power of Attorney (May Include Associate POA) 20 Nov, 2023 US8461330
Email Notification 20 Nov, 2023 US8901123
Email Notification 19 Sep, 2023 US7767675
Change in Power of Attorney (May Include Associate POA) 19 Sep, 2023 US8420645



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳